Members of the Enterobacteriaceae family are mainly involved in the etiology of urinary tract infections, and Escherichia coli is by far the most common microorganism isolated from about 50% of all nosocomial and 90% of outpatients' urinary tract infections. 1 Quinolones are effective antibacterial agents that are commonly used as antimicrobials in the management of urinary tract infections, owing to which the rates of antimicrobial resistance among E. coli strains have increased greatly during the past two decades. 1,2 Bacteria are able to develop resistance by point mutations in chromosomal genes codifying DNA gyrase and topoisomerase IV targeted by quinolones. 3 Other mechanisms involve mutations affecting the accumulation of fluoroquinolones in the bacterial cell, such as the expression of outer membrane proteins and alteration in the lipopolysaccharide. 3 Furthermore, plasmid-mediated resistance has also been identified: qnr gene products capable of protecting DNA gyrase and AAC(6¢)-Ib-cr, a variant aminoglycoside acetyltransferase, providing enzymatic antibiotic inactivation. 3 The emergence of bacterial strains exhibiting resistance against conventional antibiotics has encouraged the search for novel antimicrobial strategies. Among the compounds that are currently under investigation for their therapeutic potential are a number of antimicrobial peptides. 4 The positively charged antimicrobial peptide lactoferricin B (Lfcin B), a 25-amino-acid peptide released from the N-terminal part of bovine lactoferrin (Lf) by gastric pepsin cleavage, has recently received attention due to its broad host defense properties against bacteria, fungi and parasites. 5,6 Lfcin B is active toward Gram-positive and Gram-negative species, including E. coli. This peptide contains many hydrophobic and positively charged residues, which enable its interaction with negatively charged biological membranes. In E. coli, depolarization and large effects on the integrity of cytoplasmic membrane have been shown. 6,7 Lf and Lfcin B have been shown to be effective synergistic agents when used in combination with antibiotics. 6 Among Gram-negative bacteria, Lf enhances the sensitivity of Pseudomonas aeruginosa to chloramphenicol, 8 of Stenotrophomonas maltophilia to rifampin, 9 of Salmonella enterica to erythromycin 10 and of E. coli to novobiocin. 11 Lfcin B has been shown to act synergistically with erythromycin, 12 and a synergistic growth-inhibitory activity by bovine Lf lysate and gentamicin toward E. coli was observed. 13 In this study, we primarily analyzed the susceptibility of uropathogenic E. coli strains to fluoroquinolones. As E. coli fluoroquinolone resistance has been associated with reductions in virulence traits and shifts from the phylogenetic group B2 toward groups A, B1 or D, 2 we then compared antibiotic resistance with the strains belonging to phylogenetic groups and with the occurrence of some capsular determinants that can be considered as cell protection genes. In succession, to gain insight into the interference of...